The Role of High-Dose IL-2 in mRCC today
High-dose interleukin-2 therapy is one of the few treatments for adults with metastatic renal cell cancer (mRCC) that can produce complete responses that are often durable for decades without further therapy.1-3 We interviewed leading experts about the current status of high-dose interleukin-2 therapy,1 when and how it should be considered,4 recent developments in checkpoint inhibitor therapy to treat mRCC,5,6 the findings from a recent analysis of the PROCLAIMSM registry into the efficacy of high-dose interleukin-2 therapy in favorable-risk mRCC patients,2,7 and the impact of these developments on the overall treatment paradigm.
- Understand the importance of clinical risk factors in the treatment and management of mRCC and be aware of the current NCCN recommendations.
- Appreciate the clinical benefits and safety profile, including risks, of high-dose interleukin-2 therapy and how these may guide treatment decisions dependent on clinical risk factors.
- Demonstrate an awareness of the results of the CheckMate 214 study, showing differing survival and clinical response outcomes in patients with mRCC receiving checkpoint inhibitor therapy dependent on disease risk category.
- Understand the latest results from the PROCLAIMSM database, showing consistent survival benefits with high-dose interleukin-2 therapy across favorable, intermediate and poor-risk mRCC patients.
- Appreciate how these recent findings might alter the treatment paradigm for mRCC.
Management of MS: Let’s Get Personal
Peer-to-peer, clinically relevant, evidence-based medical educational programs – such as this acadeMe Medical Education program – filmed at the 2019 acadeMe MS Annual Conference – Management of MS: Let’s Get Personal- are critically important in our efforts to address the unmet medical education needs of the healthcare professionals responsible for the care of patients with MS. The aim of this educational resource is to enable healthcare professionals to make better-informed diagnostic and treatment decisions, ultimately resulting in improved MS patient outcomes.
Content in this section is sponsored by the pharmaceutical industry and is developed by Touch Medical Communications (TMC) for touchIMMUNOLOGY.
TMC’s mission is to provide HCPs with key education and communication through our unique Touch platform which combines clinical expertise with unparalleled society partnerships, long-term expert relationships and the Touch journal heritage, ultimately leading to fast implementation of positive clinical practice changes and improved patient outcomes. TMC’s "learner first" approach means that programming is delivered in multiple formats and can be accessed via multiple platforms, including mobile, allowing today’s on-the-go healthcare professionals to learn in the way that best suits them.
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!